| 1.6 -0.04 (-2.44%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.26 | 1-year : | 2.6 |
| Resists | First : | 1.93 | Second : | 2.23 |
| Pivot price | 1.69 |
|||
| Supports | First : | 1.46 | Second : | 1.21 |
| MAs | MA(5) : | 1.6 |
MA(20) : | 1.78 |
| MA(100) : | 2.1 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 23.2 |
D(3) : | 20.6 |
| RSI | RSI(14): 33.4 |
|||
| 52-week | High : | 9.56 | Low : | 1.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ENSC ] has closed above bottom band by 29.5%. Bollinger Bands are 39.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.65 - 1.66 | 1.66 - 1.67 |
| Low: | 1.55 - 1.56 | 1.56 - 1.57 |
| Close: | 1.59 - 1.6 | 1.6 - 1.61 |
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Tue, 02 Dec 2025
Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan
Mon, 17 Nov 2025
Ensysce Biosciences (NASDAQ: ENSC) closes $4M round, unlocking $16M for PF614 Phase 3 - Stock Titan
Fri, 14 Nov 2025
Ensysce Biosciences Reports Increased R&D Expenses Amid Net Loss - TipRanks
Fri, 14 Nov 2025
Ensysce Biosciences (NASDAQ: ENSC) begins Phase 3 PF614 trial; Q3 net loss $3.7M - Stock Titan
Tue, 13 May 2025
Ensysce Biosciences Reports First Quarter 2025 Financial Results - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 9.9 (%) |
| Shares Short | 82 (K) |
| Shares Short P.Month | 163 (K) |
| EPS | -6.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | -244.5 % |
| Operating Margin | -758.7 % |
| Return on Assets (ttm) | -109.8 % |
| Return on Equity (ttm) | -294.4 % |
| Qtrly Rev. Growth | -85.6 % |
| Gross Profit (p.s.) | -2.05 |
| Sales Per Share | 1.51 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.26 |
| PEG Ratio | 0 |
| Price to Book value | 4.21 |
| Price to Sales | 1.05 |
| Price to Cash Flow | -0.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|